With research yielding sometimes discordant findings regarding long-term medical risks of football, physicians are looking for answers for parents concerned about youth participation.
Circadian rhythm disorders, such as irregular sleep-wake rhythms, are hallmarks of Parkinson’s disease. The medical community has traditionally believed the disorders are a side effect of Parkinson’s, but a recently published study is challenging that view.
Arterial stiffness in people as young as their 40s can contribute to Alzheimer’s risk, data from the Framingham Heart Study show.
Researchers are developing a means to quickly dissolve blood clots using a drug-and-device combination that also reduces vascular injury.
The lack of a medication to treat primary-progressive multiple sclerosis (PPMS) is a source of frustration for clinicians and patients. The results of a recent phase 3 study of the drug ocrelizumab may be cause for hope.
A virtual reality game-based application is a useful tool for diagnosing mild cognitive impairment (MCI) — a condition that frequently precedes Alzheimer’s — suggests a recent study in the Journal of Alzheimer’s Disease.
A study by the National Institute of Allergy and Infectious Diseases (NIAID) yielded extended remissions for patients coping with relapsing-remitting multiple sclerosis (RRMS).
Looking for reading material for patients curious about undergoing transcranial electrical brain stimulation to improve their mood or memory? A meta-analysis by Australian researchers may be a good place to start, at least when it comes to answering questions from patients eager to improve cognition.
People who have tetraplegic spinal cord injury may not always realize when they are developing pressure ulcers. Now, a research project in Europe, Pressure Ulcer Measurement and Actuation (PUMA), has developed a device that assesses risk for pressure ulcers and suggests strategies to address that risk.
Preliminary findings from a small-scale study by Georgetown University Medical Center (GUMC) researchers indicate that a medication approved to treat leukemia may halt or reverse the progression of Parkinson’s disease and Lewy body dementia.